Treatment Satisfaction for Gene Silencing Pharmacotherapies in Hereditary Transthyretin Amyloidosis with Polyneuropathy

被引：0
|
作者：
Brown, D. [1 ]
Kessler, A. Sikora [2 ]
Llonch, M. Vera [1 ]
Yarlas, A. [2 ]
McCausland, K. [2 ]
机构：
[1] Akcea Therapeut, Boston, MA USA
[2] QualityMetric Inc LLC, Johnston, IA USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2021年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-170
引用
收藏
页码：547 / 547
页数：1
相关论文
共 50 条
  • [41] Treatment Updates for Neuropathy in Hereditary Transthyretin Amyloidosis
    King, Deandre
    Lau, K. H. Vincent
    Kaku, Michelle C.
    [J]. CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2023, 25 (06) : 137 - 149
  • [42] Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
    Dogan, Faruk Ugur
    Kurtuncu, Murat
    [J]. TURKISH JOURNAL OF NEUROLOGY, 2019, 25 (01) : 52 - 53
  • [43] New Medications in the Treatment of Hereditary Transthyretin Amyloidosis
    Walker, Scot
    [J]. HOSPITAL PHARMACY, 2018, 53 (04) : 236 - 238
  • [44] Advances in the treatment of hereditary transthyretin amyloidosis: A review
    Gertz, Morie A.
    Mauermann, Michelle L.
    Grogan, Martha
    Coelho, Teresa
    [J]. BRAIN AND BEHAVIOR, 2019, 9 (09):
  • [45] Treatment Updates for Neuropathy in Hereditary Transthyretin Amyloidosis
    Deandre King
    K. H. Vincent Lau
    Michelle C. Kaku
    [J]. Current Treatment Options in Neurology, 2023, 25 : 137 - 149
  • [46] Hereditary transthyretin amyloidosis
    Hund, E.
    [J]. NERVENARZT, 2014, 85 (10): : 1291 - 1297
  • [47] Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy
    Dyck, P. J. B.
    Coelho, T.
    Waddington Cruz, M.
    Brannagan, T.
    Khella, S.
    Karam, C.
    Berk, J. L.
    Polydefkis, M. J.
    Kincaid, J. C.
    Wiesman, J. F.
    Litchy, W. J.
    Mauermann, M. L.
    Ackermann, E. J.
    Baker, B. F.
    Jung, S. W.
    Guthrie, S.
    Pollock, M.
    Dyck, P. J.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 715 - 715
  • [48] LONGTERM TREATMENT EFFECTS OF INOTERSEN ON QUALITY OF LIFE IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY
    Brown, Duncan
    Karam, Chafic
    Yang, Min
    Done, Nicolae
    Zhu, JingJing
    Greatsinger, Ali
    Bozas, Ana
    Llonch, Montserrat Vera
    Signorovitch, James
    [J]. MUSCLE & NERVE, 2021, 64 : S57 - S57
  • [49] Evaluation of methodologies for indirect comparison of eplontersen and vutrisiran for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Karam, Chafic
    Gillmore, Julian
    Chen, Gengshi
    Jenkins, Nia
    Hale, Mike
    Taylor, Gemma
    Chen, Jersey
    Viney, Nicholas
    Schneider, Eugene
    [J]. NEUROLOGY, 2023, 100 (17)
  • [50] Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Labeyrie, Celine
    Merkel, Madeline
    Sethi, Sakshi
    Popadic, Lyuba
    Yang, Hongbo
    Sweetser, Marianne T.
    Lin, Hollis
    Adams, David
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (09)
12345